| Website | nephrogenex.com |
| Category | BioTech |
| Phone | 609-986-1780 |
| Employees |
| TOTAL | $3.3M |
| FUNDING TOTAL | $3.3M |
| Series A, 7/07 Care Capital BioStratum Vanderbilt University Office of Investments | $3.3M |
NephroGenex is a drug-development company focusing on kidney disease. The Company is developing Pyridorinâ„¢ (pyridoxamine dihydrochloride) as a treatment to slow the progression of diabetic kidney disease.
